Clinical efficacy study of position-responding mandibular advancement device in patients with obstructive sleep apnea.

IF 2.9 3区 医学 Q1 OTORHINOLARYNGOLOGY
Sung-Woon On, Dong-Kyu Kim, Min Hyuk Lee, Ji Hae Lee, Kyung Chul Lee, Soo-Hwan Byun, Seok Jin Hong
{"title":"Clinical efficacy study of position-responding mandibular advancement device in patients with obstructive sleep apnea.","authors":"Sung-Woon On, Dong-Kyu Kim, Min Hyuk Lee, Ji Hae Lee, Kyung Chul Lee, Soo-Hwan Byun, Seok Jin Hong","doi":"10.21053/ceo.2024.00124","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Although mandibular advancement device (MAD) treatment is effective in patients with obstructive sleep apnea (OSA), there are still some concerns about its potential therapeutic and side effects. Thus, we developed a novel MAD that auto-titrates depending on its position in patients with OSA. Therefore, we conducted a clinical trial to determine the efficacy of an auto-titrating mandibular advancement device (AMAD) for treating OSA.</p><p><strong>Methods: </strong>Fourteen patients with OSA were enrolled in this study. Polysomnography (PSG) was conducted at the start of the clinical trial, and PSG with AMAD in situ was performed after three months of treatment.</p><p><strong>Results: </strong>The mean Epworth Sleepiness Scale (ESS) and STOP-Bang scores were 8.21 ± 4.21 and 5.00 ± 1.00, respectively. After 3 months of treating AMAD, STOP-Bang scores improved to 3.75 ± 1.06; however, there was no significant change in ESS scores. Additionally, we found statistically significant improvements in several respiratory parameters in the PSG data after AMAD treatment. The AHI (32.85 ± 21.71 to 12.93 ± 10.70), supine AHI (45.91 ± 23.58 to 15.59 ± 12.76), lateral AHI (13.94 ± 10.95 to .49 ± 7.40), lowest O2 saturation (79.71 ± 6.22 to 84.00 ± 5.71), total arousal number (191.14 ± 112.07 to 86.57 ± 48.80), and arousal index (33.76 ± 21.00 to 15.05 ± 8.42) were recorded. However, there were no significant changes in total sleep time, sleep efficiency, or mean oxygen saturation. Additionally, we did not observe any major side effects during treatment, specifically related to tooth or jaw pain.</p><p><strong>Conclusion: </strong>Our clinical trial revealed that AMAD improved PSG parameters and reduced the incidence of common side effects. Therefore, AMAD may be an effective alternative treatment for OSA.</p>","PeriodicalId":10318,"journal":{"name":"Clinical and Experimental Otorhinolaryngology","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Otorhinolaryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21053/ceo.2024.00124","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Although mandibular advancement device (MAD) treatment is effective in patients with obstructive sleep apnea (OSA), there are still some concerns about its potential therapeutic and side effects. Thus, we developed a novel MAD that auto-titrates depending on its position in patients with OSA. Therefore, we conducted a clinical trial to determine the efficacy of an auto-titrating mandibular advancement device (AMAD) for treating OSA.

Methods: Fourteen patients with OSA were enrolled in this study. Polysomnography (PSG) was conducted at the start of the clinical trial, and PSG with AMAD in situ was performed after three months of treatment.

Results: The mean Epworth Sleepiness Scale (ESS) and STOP-Bang scores were 8.21 ± 4.21 and 5.00 ± 1.00, respectively. After 3 months of treating AMAD, STOP-Bang scores improved to 3.75 ± 1.06; however, there was no significant change in ESS scores. Additionally, we found statistically significant improvements in several respiratory parameters in the PSG data after AMAD treatment. The AHI (32.85 ± 21.71 to 12.93 ± 10.70), supine AHI (45.91 ± 23.58 to 15.59 ± 12.76), lateral AHI (13.94 ± 10.95 to .49 ± 7.40), lowest O2 saturation (79.71 ± 6.22 to 84.00 ± 5.71), total arousal number (191.14 ± 112.07 to 86.57 ± 48.80), and arousal index (33.76 ± 21.00 to 15.05 ± 8.42) were recorded. However, there were no significant changes in total sleep time, sleep efficiency, or mean oxygen saturation. Additionally, we did not observe any major side effects during treatment, specifically related to tooth or jaw pain.

Conclusion: Our clinical trial revealed that AMAD improved PSG parameters and reduced the incidence of common side effects. Therefore, AMAD may be an effective alternative treatment for OSA.

阻塞性睡眠呼吸暂停患者使用位置反应下颌前突矫正器的临床疗效研究。
目的:虽然下颌前突矫正器(MAD)对阻塞性睡眠呼吸暂停(OSA)患者的治疗效果显著,但其潜在的治疗效果和副作用仍令人担忧。因此,我们开发了一种新型下颌前突装置,可根据 OSA 患者的位置自动调整。因此,我们进行了一项临床试验,以确定自动滴定下颌前突装置(AMAD)治疗 OSA 的疗效:本研究共纳入了 14 名 OSA 患者。临床试验开始时进行多导睡眠图(PSG)检查,治疗三个月后在原位安装 AMAD 的情况下进行多导睡眠图检查:结果:埃普沃斯嗜睡量表(ESS)和 STOP-Bang 评分的平均值分别为 8.21 ± 4.21 和 5.00 ± 1.00。治疗 AMAD 3 个月后,STOP-Bang 评分提高到 3.75 ± 1.06,但 ESS 评分没有显著变化。此外,我们还发现,在 AMAD 治疗后,PSG 数据中的几个呼吸参数有了统计学意义上的明显改善。AHI(32.85 ± 21.71 到 12.93 ± 10.70)、仰卧 AHI(45.91 ± 23.58 到 15.59 ± 12.76)、侧卧 AHI(13.94 ± 10.95 到 .49 ± 7.40)、最低氧气饱和度(79.71±6.22至84.00±5.71)、总唤醒数(191.14±112.07至86.57±48.80)和唤醒指数(33.76±21.00至15.05±8.42)。然而,总睡眠时间、睡眠效率和平均血氧饱和度均无明显变化。此外,我们在治疗过程中没有观察到任何重大副作用,特别是与牙齿或下巴疼痛有关的副作用:我们的临床试验显示,AMAD 改善了 PSG 参数,降低了常见副作用的发生率。因此,AMAD 可能是治疗 OSA 的有效替代疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
6.70%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is an international peer-reviewed journal on recent developments in diagnosis and treatment of otorhinolaryngology-head and neck surgery and dedicated to the advancement of patient care in ear, nose, throat, head, and neck disorders. This journal publishes original articles relating to both clinical and basic researches, reviews, and clinical trials, encompassing the whole topics of otorhinolaryngology-head and neck surgery. CEO was first issued in 2008 and this journal is published in English four times (the last day of February, May, August, and November) per year by the Korean Society of Otorhinolaryngology-Head and Neck Surgery. The Journal aims at publishing evidence-based, scientifically written articles from different disciplines of otorhinolaryngology field. The readership contains clinical/basic research into current practice in otorhinolaryngology, audiology, speech pathology, head and neck oncology, plastic and reconstructive surgery. The readers are otolaryngologists, head and neck surgeons and oncologists, audiologists, and speech pathologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信